The latest price and purchase method of Ensartinib in 2025

Ensartinib is a domestically produced ALKtyrosine kinase inhibitor, mainly used to treat ALK-positive non-small cell lung cancer (NSCLC) patients. Ensartinib has been successfully launched in mainland China by Betta Pharmaceuticals, with the trade name Icotinib (Alunbrig). The launch of this drug provides more treatment options for the majority of patients. Especially for those patients who are resistant to or intolerant to traditional chemotherapy, ensartinib provides an effective new option for targeted therapy.

In terms of price, ensartinib, as a domestic drug, is more competitive than imported similar drugs. The general market price ranges from a few hundred yuan to more than a thousand yuan per box. The specific price will vary depending on the region, hospital and sales channel. More importantly, ensartinib has been included in China’s national medical insurance Category B catalog, and eligible patients can enjoy the medical insurance reimbursement policy, which greatly reduces the financial burden on patients. The implementation of this policy allows more patients to afford high-quality targeted drug treatment and improves the accessibility and sustainability of treatment.

Ensartinib has a wide range of purchase channels, and patients can purchase it through pharmacies in major tertiary hospitals, medical insurance designated pharmacies, and legal online drug platforms. Before purchasing, patients should consult their attending doctor in detail to confirm whether the medication plan is suitable for their condition, and understand the relevant policies and procedures for medical insurance reimbursement. In addition, patients should choose formal channels to purchase drugs and avoid obtaining drugs through informal channels to ensure drug quality and medication safety.

Overall, the domestic launch of ensartinib has greatly promoted the development of targeted therapy for ALK positive lung cancer. Patients should maintain close communication with their doctors during use, conduct regular efficacy and safety assessments, and make reasonable adjustments to treatment plans. In the future, with the accumulation of more clinical data and the improvement of medical insurance policies, ensartinib is expected to help more patients achieve better treatment effects and improve their quality of life, becoming a benchmark product for domestic targeted treatment of lung cancer.

Reference materials:https://www.drugs.com/